RESMED ($RMD) is expected to release its quarterly earnings data on Thursday, January 29th after market close, per Finnhub. Analysts are expecting revenue of $1,410,287,118 and earnings of $2.75 per share.
You can see Quiver Quantitative's $RMD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
RESMED Insider Trading Activity
RESMED insiders have traded $RMD stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $RMD stock by insiders over the last 6 months:
- MICHAEL J. FARRELL (Chairman and CEO) has made 0 purchases and 6 sales selling 42,020 shares for an estimated $11,226,935.
- BRETT SANDERCOCK (Chief Financial Officer) has made 0 purchases and 6 sales selling 14,000 shares for an estimated $3,709,620.
- PETER C FARRELL has made 0 purchases and 3 sales selling 6,000 shares for an estimated $1,504,700.
- JOHN HERNANDEZ sold 2,575 shares for an estimated $739,289
- WITTE JAN DE has made 0 purchases and 2 sales selling 2,542 shares for an estimated $645,896.
- MICHAEL J RIDER (Global General Counsel) has made 0 purchases and 3 sales selling 150 shares for an estimated $38,390.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
RESMED Revenue
RESMED had revenues of $1.3B in Q1 2026. This is an increase of 9.07% from the same period in the prior year.
You can track RMD financials on Quiver Quantitative's RMD stock page.
RESMED Hedge Fund Activity
We have seen 423 institutional investors add shares of RESMED stock to their portfolio, and 433 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 773,400 shares (+74.4%) to their portfolio in Q3 2025, for an estimated $211,702,782
- FMR LLC added 535,507 shares (+155.3%) to their portfolio in Q3 2025, for an estimated $146,584,331
- BANK OF NEW YORK MELLON CORP removed 492,643 shares (-9.8%) from their portfolio in Q3 2025, for an estimated $134,851,168
- PRICE T ROWE ASSOCIATES INC /MD/ added 429,050 shares (+125.0%) to their portfolio in Q3 2025, for an estimated $117,443,856
- MORGAN STANLEY removed 347,095 shares (-13.0%) from their portfolio in Q3 2025, for an estimated $95,010,314
- UBS GROUP AG added 339,774 shares (+63.7%) to their portfolio in Q3 2025, for an estimated $93,006,337
- FIRST TRUST ADVISORS LP added 329,588 shares (+285.1%) to their portfolio in Q3 2025, for an estimated $90,218,123
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
RESMED Analyst Ratings
Wall Street analysts have issued reports on $RMD in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 10/31/2025
- RBC Capital issued a "Outperform" rating on 10/31/2025
- Morgan Stanley issued a "Overweight" rating on 10/21/2025
- Citigroup issued a "Buy" rating on 09/18/2025
- UBS issued a "Buy" rating on 08/01/2025
To track analyst ratings and price targets for RESMED, check out Quiver Quantitative's $RMD forecast page.
RESMED Price Targets
Multiple analysts have issued price targets for $RMD recently. We have seen 10 analysts offer price targets for $RMD in the last 6 months, with a median target of $299.5.
Here are some recent targets:
- Jonathan Block from Stifel set a target price of $260.0 on 12/18/2025
- Joe Vruwink from Baird set a target price of $275.0 on 12/16/2025
- Brett Fishbin from Keybanc set a target price of $299.0 on 10/31/2025
- Anthony Petrone from Mizuho set a target price of $300.0 on 10/31/2025
- Craig Wong-Pan from RBC Capital set a target price of $303.0 on 10/31/2025
- Sean Laaman from Morgan Stanley set a target price of $304.0 on 10/21/2025
- Nathan Treybeck from Wells Fargo set a target price of $280.0 on 10/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
